文献速递淋巴瘤

停用伊布替尼的套细胞淋巴瘤(MCL)患者的长期结局与突变谱分析

Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
PubMed 文献 · Br J Haematol · 2018-09-02

该研究纳入80例因各种原因停用伊布替尼的套细胞淋巴瘤(MCL)患者,中位随访38个月,并对15例患者(含5对进展前后配对样本)行深部靶向二代测序。停药后中位生存:疾病进展者10个月、转化者6个月、不耐受者25个月;进展后BTK突变见于17%患者,TP53改变见于75%患者。

要点

  • 停用伊布替尼后中位随访38个月,中位用药时长7.6个月。
  • 停药原因:疾病进展/转化51%、不耐受25%、患者选择9%、干细胞移植6%、第二肿瘤5%、其他4%。
  • 进展后BTK突变17%,TP53改变75%;4例母细胞样转化中3例(75%)有NSD2突变(与TP53共存)。

核心结论

  • 伊布替尼难治性MCL患者生存期短,疾病进展与转化后中位生存分别为10个月与6个月。
  • 在发生母细胞样转化的患者中检出TP53与NSD2突变、在进展患者中检出ATM与TP53突变,为伊布替尼难治性MCL的未来研究提供了方向。

研究设计与样本

  • 对15例MCL患者(含5例伊布替尼进展前后配对样本)行深部靶向二代测序的体细胞突变谱分析。
  • 识别80例因各种原因停用伊布替尼治疗的MCL患者,停药后中位随访38个月。

主要发现

  • 停用伊布替尼原因:疾病进展/转化41例(51%)、不耐受20例(25%)、患者选择7例(9%)、干细胞移植5例(6%)、第二肿瘤4例(5%)、其他原因3例(4%)。
  • 伊布替尼中位用药时长7.6个月;停药后中位生存:疾病进展者10个月、转化者6个月、不耐受者25个月。
  • 伊布替尼进展后BTK突变见于17%患者,TP53改变见于75%患者。
  • 4例母细胞样转化患者中3例(75%)有NSD2突变,且与TP53共存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Long term outcomes and mutations in patients with mantle cell lymphoma (MCL) who discontinued ibrutinib have not been described. Using deep targeted next generation sequencing, we performed somatic mutation profiling from 15 MCL patients (including 5 patients with paired samples; before and after progression on ibrutinib). We identified 80 patients with MCL who discontinued ibrutinib therapy for various reasons. Median follow-up after ibrutinib discontinuation was 38 months. The median duration on ibrutinib was 7·6 months. Forty-one (51%) patients discontinued ibrutinib due to disease progression/transformation, 20 (25%) for intolerance, 7 (9%) due to patient choice, 5 (6%) for stem cell transplant, 4 (5%) due to second cancers and 3 (4%) other causes. The median survival after ibrutinib was 10 and 6 months for disease progression and transformation, respectively, and 25 months for patients with ibrutinib intolerance. Overall, BTK mutations were observed in 17% patients after progression on ibrutinib. Notably, TP53 alterations were observed after progression in 75% patients. Among the 4 patients with blastoid transformation, 3 (75%) had NSD2 mutations (co-existing with TP53). Ibrutinib-refractory MCL patients had a short survival. Demonstration of TP53 and NSD2 mutations in patients who developed blastoid transformation and ATM and TP53 mutations in patients who progressed, opens the door for future investigations in ibrutinib-refractory MCL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Jain P, Kanagal-Shamanna R, Zhang S, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018. PMID: 30175400. doi:10.1111/bjh.15567

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。